Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LURBINECTEDIN for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8 adverse event reports in the FDA FAERS database where LURBINECTEDIN was used for Neoplasm malignant.

Most Reported Side Effects for LURBINECTEDIN

Side Effect Reports % Deaths Hosp.
Death 129 13.4% 129 11
Disease progression 98 10.1% 28 14
Off label use 69 7.1% 6 10
Neutropenia 59 6.1% 12 28
Nausea 58 6.0% 5 15
Thrombocytopenia 48 5.0% 9 22
Fatigue 43 4.5% 3 5
Febrile neutropenia 39 4.0% 9 29
Vomiting 37 3.8% 5 14
Asthenia 36 3.7% 1 13
Anaemia 34 3.5% 5 16
Injection site reaction 32 3.3% 0 0
Acute kidney injury 28 2.9% 7 24
Pneumonia 27 2.8% 11 19
Diarrhoea 25 2.6% 4 12

Other Indications for LURBINECTEDIN

Small cell lung cancer (351) Product used for unknown indication (250) Small cell lung cancer metastatic (106) Small cell lung cancer extensive stage (56) Lung neoplasm malignant (41) Bladder cancer (11) Bronchial carcinoma (10) Small cell carcinoma (7) Small cell lung cancer recurrent (7) Lung carcinoma cell type unspecified stage 0 (6)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

LURBINECTEDIN Full Profile All Neoplasm malignant Drugs LURBINECTEDIN Demographics LURBINECTEDIN Timeline